We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Ulrika
Aberg
0046701679744
ulrika.aberg@uu.se
Prof
Anna
Bill-Axelson
More information about this study, what is involved and how to take part can be found on the study website.
Active surveillance for low-risk and favourable intermediate-risk prostate cancer
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Prostate cancer is the most common cancer in men in the Western world. If prostate cancer is detected when it is at an early stage and not causing any symptoms, treatment is not immediately needed. Instead the patient’s condition is carefully monitored (active surveillance) with blood tests (the PSA test), physical examination of the prostate, and taking a small sample of tissue (a biopsy) from the prostate. There is however a problematic knowledge gap surrounding active surveillance, and the most important piece of evidence missing is when treatment is likely to be needed and beneficial for the patient. Moreover, the optimal follow-up programs are not yet defined. The aim of this study is to compare current practice of active surveillance with a standardised program for follow-up and triggers for treatment. It is believed that standardised criteria for treatment will reduce unnecessary treatment of early stage prostate cancer, without increasing the risk of not being cured in time. Patients can safely be followed-up by nurses, which increase continuity. Standardised, evidence-based active surveillance programs can also decrease inequities of health care in and between countries.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2019 Protocol article in http://dx.doi.org/10.1136/bmjopen-2018-027860 protocol (added 21/09/2020)
You can take part if:
You may not be able to take part if:
Participants not fulfilling the inclusion criteria
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Ulrika
Aberg
0046701679744
ulrika.aberg@uu.se
Prof
Anna
Bill-Axelson
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Uppsala University and funded by Cancerfonden; Svenska Forskningsrådet Formas; Nordic Cancer Union.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
